drugset / Trial / NCT00273533

Ramipril in Rheumatoid Arthritis

NCT00273533

Phase 2/3 Completed 13 enrolled University of Zurich Sanofi · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The present study is designed to evaluate the hypothesis that the Angiotensin-Converting Enzyme (ACE) inhibitor Ramipril improves vascular function and reduces markers of low-grade chronic inflammation and oxidative stress in patients with Rheumatoid Arthritis.

Timeline

Start
2004-06
Primary completion
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramipril Small molecule 10 mg

Indications